This randomized , double-blind , placebo-controlled trial comprised a single-dose assessment of lixisenatide 5 and 10g , and a 5 - to 6-week repeated dose-escalation assessment of lixisenatide 5 to 30g once ( QD ) or twice daily ( BID ) .